🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9 results for “pirtobrutinib” Clear

  1. IBRUTINIB, PIRTOBRUTINIB, PIRTOBRUTINIB

    Ology Bioservices Ireland LTD

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  2. PIRTOBRUTINIB, IBRUTINIB, PIRTOBRUTINIB, IBRUTINIB

    Ology Bioservices Ireland LTD

    Mantle cell lymphoma

    phase 3 small molecule active

    1 trial

  3. PIRTOBRUTINIB, IDELALISIB, RITUXIMAB, BENDAMUSTINE HYDROCHLORIDE, PIRTOBRUTINIB, IDELALISIB

    Ology Bioservices Ireland LTD

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  4. PIRTOBRUTINIB, RITUXIMAB, PIRTOBRUTINIB, BENDAMUSTINE

    Ology Bioservices Ireland LTD

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  5. VENETOCLAX, RITUXIMAB, PIRTOBRUTINIB, PIRTOBRUTINIB, VENETOCLAX

    Ology Bioservices Ireland LTD

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

    phase 3 small molecule active

    1 trial

  6. PIRTOBRUTINIB

    Fondazione Telethon ETS

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  7. Pirtobrutinib, Placebo tablets

    Eli Lilly Co.

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  8. Polivy 30 mg powder for concentrate for solution for infusion., Epcoritamab (GEN3013), Truxima 100 mg concentrate for solution for infusion, IMBRUVICA 140 mg hard capsules, Golcadomide, Revlimid 10 mg hard capsules, IMBRUVICA 140 mg hard capsules, PIRTOBRUTINIB, Cyclophosphamide Injection 500 mg., Venetoclax, Venetoclax, Epcoritamab (GEN3013), Revlimid 25 mg hard capsules, Venetoclax, Decortin® H 20 mg Tabletten, Truxima 500 mg concentrate for solution for infusion, Decortin® H 5 mg Tabletten, Adriblastin®

    AbbVie Deutschland GmbH & Co. KG

    B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma

    phase 2 small molecule active

    1 trial

  9. A Study to Test How Safe, Effective and How Body’s Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

    Roche Registration Limited

    Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL)

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources